Home » Stocks » Repare Therapeutics

Repare Therapeutics, Inc. (RPTX)

Stock Price: $31.05 USD 0.91 (3.02%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.14B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 36.75M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 25, 2020
Last Price $31.05
Previous Close $30.14
Change ($) 0.91
Change (%) 3.02%
Day's Open 30.72
Day's Range 29.22 - 33.29
Day's Volume 36,062
52-Week Range 21.45 - 36.67

More Stats

Market Cap 1.14B
Enterprise Value 771.81M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 36.75M
Float 17.44M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 715,264
Short Ratio 18.77
Short % of Float 4.68%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.53
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 369.39M
Net Cash / Share 10.05
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(17.55% upside)
Current: $31.05
Target: 36.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-26.38-12.82-6.18
Net Income-27.22-14.28-7.80
Shares Outstanding1.531.531.52
Earnings Per Share-17.81-9.35-5.12
Operating Cash Flow-18.43-12.62-6.01
Capital Expenditures-1.30-0.58-1.16
Free Cash Flow-19.73-13.20-7.16
Cash & Equivalents95.0110.930.00
Total Debt1.06--
Net Cash / Debt93.9410.930.00
Book Value-46.13-22.38-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Repare Therapeutics, Inc.
Country Canada
Employees 69
CEO Lloyd M. Segal

Stock Information

Ticker Symbol RPTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RPTX
IPO Date June 19, 2020


Repare Therapeutics, a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing CCNE1-SL inhibitor, a proprietary drug discovery program for tumors with amplification of CCNE1; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was founded in 2016 and is headquartered in Montréal, Canada.